Robert E. Bristow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert E. Bristow has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Jenny Chang
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, School of Medicine, and the Chao Family Comprehensive Cancer Center, Orange, and the Department of Medicine, University of California, Irvine, School of Medicine, and the Program in Public Health, Susan and Henry Samueli College of Health Sciences, University of California, Irvine, Irvine, California
9 shared publicationsArgyrios Ziogas
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, School of Medicine, and the Chao Family Comprehensive Cancer Center, Orange, and the Department of Medicine, University of California, Irvine, School of Medicine, and the Program in Public Health, Susan and Henry Samueli College of Health Sciences, University of California, Irvine, Irvine, California
6 shared publicationsHoda Anton-Culver
Department of Epidemiology, University of California, Irvine - School of Medicine, Irvine, CA
6 shared publicationsAlan Smith
Applied Clinical Intelligence, Bala Cynwyd, PA
4 shared publications- Argyrios Ziogas
Department of Medicine, University of California Irvine, Irvine, CA, USA
4 shared publications Donald G. Munroe
Vermillion Inc, Austin, TX
4 shared publications
Latest Publications
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Hyperthermic Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer: A Systemic Review and Meta-Analysis
Background: The value of hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC) is controversial and its use remains experimental in most national and international guidelines. We wished to systematically evaluate all available evidence.Methods: A comprehensive review of data from MEDLINE, EMBASE, and Cochrane Library databases was conducted from the first report on HIPEC in EOC till 2021. We included relevant studies on primary or relapsed EOC- patients – across all stages- that met the following criteria: randomized controlled trials, case-control studies, or two-arm cohort studies; and studies that compared progression-free survival (PFS) or overall survival (OS) between patients who underwent CRS plus HIPEC and those who underwent CRS alone. PFS and OS were compared between the HIPEC- and control groups. Findings: Fifteen studies (10 case-control studies and 5 RCTs) were included in the present meta-analysis. Based on the time interval between the last systemic chemotherapy exposure and timing of CRS +/- HIPEC, all studies and patients cohorts we classified into recent (<6 months; n=9 studies/patients cohorts) and non-recent (≥6 months, n=8 studies/patients cohorts) chemotherapy exposure groups. In the recent chemotherapy exposure group, HIPEC was associated with improvement of both PFS (HR, 0.621; 95% CI, 0.513−0.753) and OS (HR, 0.519; 95% CI, 0.346−0.777). On the contrary, in the non-recent chemotherapy exposure group, HIPEC failed to significantly affect PFS (HR, 1.037; 95% CI, 0.684−1.571) or OS (HR, 0.932; 95% CI, 0.607-1.430). Consistent results were observed in subsequent sensitivity analyses.Interpretation: Our present meta-analysis demonstrates that the value of HIPEC at CRS for EOC appears to depend on the timing of the last systemic chemotherapy exposure. Future trials are awaited to define the role of HIPEC in EOC.Registration Details: This meta-analysis was registered with PROSPERO (CRD42021265810).Funding Information: The study was funded by the National Cancer Center Korea (NCC 2110790). The funder had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.Declaration of Interests: Dr. Lim reported having a consulting or advisory role for AstraZeneca, Boryung, CKD Pharm, Genexine, Hospicare, GI Innovation, and Takeda and receiving research funding from AbbVie, Amgen, Astellas, AstraZeneca, BeiGene, Cellid, CKD Pharm, Clovis, Eisai, Genexine, GSK, Incyte, Merck, MSD, OncoQuest, Pfizer, and Roche outside the submitted work. Dr. Park reported having a consulting or advisory role for Boryung and Takeda and receiving research funding from AbbVie, Amgen, Astellas, AstraZeneca, BeiGene, Cellid, CKD Pharm, Clovis, Eisai, Genexine, GSK, Incyte, Merck, MSD, OncoQuest, Pfizer, and Roche outside the submitted work. No other disclosures were reported. Dr. Fotopoulou reported a consulting or advisory role for GlaxoSmithKline, Roche/Genentech, Clovis Oncology, AstraZeneca, Global Oncology One, Aptitude Health, Eisai, and research funding from Myrovlytis Charity Trust. Other authors declare they have no conflicts of interest relevant to this article.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessHyperthermic Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer: A Systemic Review and Meta-Analysis
Background: The value of hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC) is controversial and its use remains experimental in most national and international guidelines. We wished to systematically evaluate all available evidence.Methods: A comprehensive review of data from MEDLINE, EMBASE, and Cochrane Library databases was conducted from the first report on HIPEC in EOC till 2021. We included relevant studies on primary or relapsed EOC- patients – across all stages- that met the following criteria: randomized controlled trials, case-control studies, or two-arm cohort studies; and studies that compared progression-free survival (PFS) or overall survival (OS) between patients who underwent CRS plus HIPEC and those who underwent CRS alone. PFS and OS were compared between the HIPEC- and control groups. Findings: Fifteen studies (10 case-control studies and 5 RCTs) were included in the present meta-analysis. Based on the time interval between the last systemic chemotherapy exposure and timing of CRS +/- HIPEC, all studies and patients cohorts we classified into recent (<6 months; n=9 studies/patients cohorts) and non-recent (≥6 months, n=8 studies/patients cohorts) chemotherapy exposure groups. In the recent chemotherapy exposure group, HIPEC was associated with improvement of both PFS (HR, 0.621; 95% CI, 0.513−0.753) and OS (HR, 0.519; 95% CI, 0.346−0.777). On the contrary, in the non-recent chemotherapy exposure group, HIPEC failed to significantly affect PFS (HR, 1.037; 95% CI, 0.684−1.571) or OS (HR, 0.932; 95% CI, 0.607-1.430). Consistent results were observed in subsequent sensitivity analyses.Interpretation: Our present meta-analysis demonstrates that the value of HIPEC at CRS for EOC appears to depend on the timing of the last systemic chemotherapy exposure. Future trials are awaited to define the role of HIPEC in EOC.Registration Details: This meta-analysis was registered with PROSPERO (CRD42021265810).Funding Information: The study was funded by the National Cancer Center Korea (NCC 2110790). The funder had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.Declaration of Interests: Dr. Lim reported having a consulting or advisory role for AstraZeneca, Boryung, CKD Pharm, Genexine, Hospicare, GI Innovation, and Takeda and receiving research funding from AbbVie, Amgen, Astellas, AstraZeneca, BeiGene, Cellid, CKD Pharm, Clovis, Eisai, Genexine, GSK, Incyte, Merck, MSD, OncoQuest, Pfizer, and Roche outside the submitted work. Dr. Park reported having a consulting or advisory role for Boryung and Takeda and receiving research funding from AbbVie, Amgen, Astellas, AstraZeneca, BeiGene, Cellid, CKD Pharm, Clovis, Eisai, Genexine, GSK, Incyte, Merck, MSD, OncoQuest, Pfizer, and Roche outside the submitted work. No other disclosures were reported. Dr. Fotopoulou reported a consulting or advisory role for GlaxoSmithKline, Roche/Genentech, Clovis Oncology, AstraZeneca, Global Oncology One, Aptitude Health, Eisai, and research funding from Myrovlytis Charity Trust. Other authors declare they have no conflicts of interest relevant to this article.
- 1 August 2021
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 33 (4) , 355-359
Looking at cancer health disparities in gynecologic oncology in 2020
Purpose of review: To summarize the most recent evidence on gynecologic cancer disparities and to describe studies investigating the social determinants of health and receipt of evidence-based care and potential interventions to address inequities in care. Recent findings: Significant disparities in disease-specific survival by race/ethnicity, socioeconomic status, and payer status have persisted in women with gynecologic cancers. Compared with white women, black women have an increased likelihood of disease-specific mortality for endometrial cancer and are less likely to receive guideline-adherent care for ovarian cancer. The Covid-19 pandemic has brought significant attention to the structural barriers that contribute to persistent health disparities and how community-based partnerships with a focus on policy interventions are needed for equitable gynecologic cancer outcomes. Summary: In this review, we discuss structural barriers contributing to racial inequities, the role of Medicaid payer status and receipt of quality cancer care, gender, and racial workforce diversity, and community-based partnerships to create evidence-based interventions to address disparities.
- 1 August 2021
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 33 (4) , 355-359
Looking at cancer health disparities in gynecologic oncology in 2020
Purpose of review: To summarize the most recent evidence on gynecologic cancer disparities and to describe studies investigating the social determinants of health and receipt of evidence-based care and potential interventions to address inequities in care. Recent findings: Significant disparities in disease-specific survival by race/ethnicity, socioeconomic status, and payer status have persisted in women with gynecologic cancers. Compared with white women, black women have an increased likelihood of disease-specific mortality for endometrial cancer and are less likely to receive guideline-adherent care for ovarian cancer. The Covid-19 pandemic has brought significant attention to the structural barriers that contribute to persistent health disparities and how community-based partnerships with a focus on policy interventions are needed for equitable gynecologic cancer outcomes. Summary: In this review, we discuss structural barriers contributing to racial inequities, the role of Medicaid payer status and receipt of quality cancer care, gender, and racial workforce diversity, and community-based partnerships to create evidence-based interventions to address disparities.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (3) , e51
Rectosigmoid resection by gynecologic oncologists versus colorectal surgeons: as long as it catches the mouse, does the color of the cat matter?
Chang SJ, et al. J Gynecol Oncol. 2020 Oct;32:e51. https://doi.org/10.3802/jgo.2021.32.e51
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (3) , e51
Open AccessRectosigmoid resection by gynecologic oncologists versus colorectal surgeons: as long as it catches the mouse, does the color of the cat matter?
Chang SJ, et al. J Gynecol Oncol. 2020 Oct;32:e51. https://doi.org/10.3802/jgo.2021.32.e51
- 1 January 2021
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 30 (1) , 69-88
Surgical Management of Gynecologic Cancers
- 1 January 2021
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 30 (1) , 69-88
Surgical Management of Gynecologic Cancers
- 3 October 2020
- Published by Elsevier in Cancer Epidemiology
- Vol. 69, 101825
Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996–2014
- 3 October 2020
- Published by Elsevier in Cancer Epidemiology
- Vol. 69, 101825
Ovarian cancer in California: Guideline adherence, survival, and the impact of geographic location, 1996–2014
- Open Access
- 9 February 2020
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 135 (2) , 328-339
A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals
OBJECTIVE: To validate the observed/expected ratio for adherence to ovarian cancer treatment guidelines as a risk-adjusted measure of hospital quality care, and to identify patient characteristics associated with disparities in access to high-performing hospitals. METHODS: This was a retrospective population-based study of stage I–IV invasive epithelial ovarian cancer reported to the California Cancer Registry between 1996 and 2014. A fit logistic regression model, which was risk-adjusted for patient and disease characteristics, was used to calculate the observed/expected ratio for each hospital, stratified by hospital annual case volume. A Cox proportional hazards model was used for survival analyses, and a multivariable logistic regression model was used to identify independent predictors of access to high-performing hospitals. RESULTS: The study population included 30,051 patients who were treated at 426 hospitals: low observed/expected ratio (n=304) 23.5% of cases; intermediate observed/expected ratio (n=92) 57.8% of cases; and high observed/expected ratio (n=30) 18.7% of cases. Hospitals with high observed/expected ratios were significantly more likely to deliver guideline-adherent care (53.3%), compared with hospitals with intermediate (37.8%) and low (27.5%) observed/expected ratios (P<.001). Median disease-specific survival time ranged from 73.0 months for hospitals with high observed/expected ratios to 48.1 months for hospitals with low observed/expected ratios (P<.001). Treatment at a hospital with a high observed/expected ratio was an independent predictor of superior survival compared with hospitals with intermediate (hazard ratio [HR] 1.06, 95% CI 1.01–1.11, P<.05) and low (HR 1.10, 95% CI 1.04–1.16, P<.001) observed/expected ratios. Being of Hispanic ethnicity (odds ratio [OR] 0.85, 95% CI 0.78–0.93, P<.001, compared with white), having Medicare insurance (OR 0.74, 95% CI 0.68–0.81 P<.001, compared with managed care), having a Charlson Comorbidity Index score of 2 or greater (OR 0.91, 95% CI 0.83–0.99, P<.05), and being of lower socioeconomic status (lowest quintile OR 0.41, 95% CI 0.36–0.46, P<.001, compared with highest quintile) were independent negative predictors of access to a hospital with a high observed/expected ratio. CONCLUSION: Ovarian cancer care at a hospital with a high observed/expected ratio is an independent predictor of improved survival. Barriers to high-performing hospitals disproportionately affect patients according to sociodemographic characteristics. Triage of patients with suspected ovarian cancer according to a performance-based observed/expected ratio hospital classification is a potential mechanism for expanded access to expert care.
- 9 February 2020
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 135 (2) , 328-339
Open AccessA Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals
OBJECTIVE: To validate the observed/expected ratio for adherence to ovarian cancer treatment guidelines as a risk-adjusted measure of hospital quality care, and to identify patient characteristics associated with disparities in access to high-performing hospitals. METHODS: This was a retrospective population-based study of stage I–IV invasive epithelial ovarian cancer reported to the California Cancer Registry between 1996 and 2014. A fit logistic regression model, which was risk-adjusted for patient and disease characteristics, was used to calculate the observed/expected ratio for each hospital, stratified by hospital annual case volume. A Cox proportional hazards model was used for survival analyses, and a multivariable logistic regression model was used to identify independent predictors of access to high-performing hospitals. RESULTS: The study population included 30,051 patients who were treated at 426 hospitals: low observed/expected ratio (n=304) 23.5% of cases; intermediate observed/expected ratio (n=92) 57.8% of cases; and high observed/expected ratio (n=30) 18.7% of cases. Hospitals with high observed/expected ratios were significantly more likely to deliver guideline-adherent care (53.3%), compared with hospitals with intermediate (37.8%) and low (27.5%) observed/expected ratios (P<.001). Median disease-specific survival time ranged from 73.0 months for hospitals with high observed/expected ratios to 48.1 months for hospitals with low observed/expected ratios (P<.001). Treatment at a hospital with a high observed/expected ratio was an independent predictor of superior survival compared with hospitals with intermediate (hazard ratio [HR] 1.06, 95% CI 1.01–1.11, P<.05) and low (HR 1.10, 95% CI 1.04–1.16, P<.001) observed/expected ratios. Being of Hispanic ethnicity (odds ratio [OR] 0.85, 95% CI 0.78–0.93, P<.001, compared with white), having Medicare insurance (OR 0.74, 95% CI 0.68–0.81 P<.001, compared with managed care), having a Charlson Comorbidity Index score of 2 or greater (OR 0.91, 95% CI 0.83–0.99, P<.05), and being of lower socioeconomic status (lowest quintile OR 0.41, 95% CI 0.36–0.46, P<.001, compared with highest quintile) were independent negative predictors of access to a hospital with a high observed/expected ratio. CONCLUSION: Ovarian cancer care at a hospital with a high observed/expected ratio is an independent predictor of improved survival. Barriers to high-performing hospitals disproportionately affect patients according to sociodemographic characteristics. Triage of patients with suspected ovarian cancer according to a performance-based observed/expected ratio hospital classification is a potential mechanism for expanded access to expert care.
- 1 January 2020
- Published by Elsevier in Lung Cancer
- Vol. 139, S86-S87
Implementing electronic patient reported outcome measures (ePROMs) into routine lung cancer follow-up: the patient perspective
- 1 January 2020
- Published by Elsevier in Lung Cancer
- Vol. 139, S86-S87
Implementing electronic patient reported outcome measures (ePROMs) into routine lung cancer follow-up: the patient perspective
- Open Access
- 8 August 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 800
Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study
In this retrospective study, data from patients listed in the Korea Central Cancer Registry during 1993–2014 were analysed, to investigate the incidence and survival of second primary cancers (SPCs) after a diagnosis of primary peritoneal, epithelial ovarian, and fallopian tubal (POFT) cancer. The standardised incidence ratio (SIR) and survival outcomes of patients with SPCs among POFT cancer survivors were analysed. Among 20,738 POFT cancer survivors, 798 (3.84%) developed SPCs, at an average interval of 5.50 years. SPC risk in POFT survivors (SIR, 1.29) was higher compared to the general population. The most high-risk type of SPC was leukaemia (3.07) followed by the lung and bronchus (1.80), colon (1.58), rectum and rectosigmoid junction (1.42), thyroid (1.34), and breast (1.26). In women aged < 60 years, cancer of the breast (1.30), ascending colon (2.26), and transverse colon (4.07) as SPCs increased. Up to 10 years after POFT cancer treatment, leukaemia risk increased, especially in those < 60 years, with serous histology, and with distant stage, which required aggressive chemotherapy. The median overall survival time was 12.8 years and 14.3 years in women with POFT cancer and SPCs, respectively. Thyroid and breast cancers were favourable prognostic markers among SPCs. The overall SPC risk increases in POFT cancer survivors, especially in those < 60 years. The cancer risk of breast and the proximal colon increase based on hereditary predisposition, while leukaemia likely develops from aggressive treatment. The median overall survival is favourable in POFT cancer survivors with SPCs.
- 8 August 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 800
Open AccessSecond primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study
In this retrospective study, data from patients listed in the Korea Central Cancer Registry during 1993–2014 were analysed, to investigate the incidence and survival of second primary cancers (SPCs) after a diagnosis of primary peritoneal, epithelial ovarian, and fallopian tubal (POFT) cancer. The standardised incidence ratio (SIR) and survival outcomes of patients with SPCs among POFT cancer survivors were analysed. Among 20,738 POFT cancer survivors, 798 (3.84%) developed SPCs, at an average interval of 5.50 years. SPC risk in POFT survivors (SIR, 1.29) was higher compared to the general population. The most high-risk type of SPC was leukaemia (3.07) followed by the lung and bronchus (1.80), colon (1.58), rectum and rectosigmoid junction (1.42), thyroid (1.34), and breast (1.26). In women aged < 60 years, cancer of the breast (1.30), ascending colon (2.26), and transverse colon (4.07) as SPCs increased. Up to 10 years after POFT cancer treatment, leukaemia risk increased, especially in those < 60 years, with serous histology, and with distant stage, which required aggressive chemotherapy. The median overall survival time was 12.8 years and 14.3 years in women with POFT cancer and SPCs, respectively. Thyroid and breast cancers were favourable prognostic markers among SPCs. The overall SPC risk increases in POFT cancer survivors, especially in those < 60 years. The cancer risk of breast and the proximal colon increase based on hereditary predisposition, while leukaemia likely develops from aggressive treatment. The median overall survival is favourable in POFT cancer survivors with SPCs.
- 15 March 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 149 (3) , 525-530
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study
- 15 March 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 149 (3) , 525-530
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study